These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24782260)

  • 41. Update on hepatitis C treatment in HIV-coinfected patients.
    Camino N; Sheldon J; Soriano V
    Minerva Gastroenterol Dietol; 2004 Mar; 50(1):67-77. PubMed ID: 15719008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
    De Leon LB; Tovo CV; Kliemann DA; De Mattos AA; Feltrin AA; Pacheco LS; De Almeida PR
    J Infect Dev Ctries; 2016 Aug; 10(7):762-9. PubMed ID: 27482809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIV and HCV Therapies in 2016: Optimal Regimens.
    Sasadeusz J
    AIDS Rev; 2016; 18(4):212-221. PubMed ID: 27438581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The clinical management of HCV in the HIV-infected patient.
    Norton B; Naggie S
    Antivir Ther; 2015; 20(5):457-67. PubMed ID: 25346056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
    Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK;
    J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1117-28. PubMed ID: 23199398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
    Sauleda S; Juárez A; Esteban JI; Altisent C; Ruiz I; Puig L; Esteban R; Guardia J
    Hepatology; 2001 Nov; 34(5):1035-40. PubMed ID: 11679976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.
    Jiménez-Sousa MA; Rallón N; Berenguer J; Pineda-Tenor D; López JC; Soriano V; Guzmán-Fulgencio M; Cosín J; Retana D; García-Álvarez M; Miralles P; Benito JM; Resino S
    J Clin Virol; 2015 Apr; 65():62-7. PubMed ID: 25766991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of the hepatitis C virus in patients coinfected with HIV.
    Khalili M; Proietti N
    Gastroenterol Clin North Am; 2004 Sep; 33(3):479-96, vii-viii. PubMed ID: 15324939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus.
    Piroth L
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S75-83. PubMed ID: 22248699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
    Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM;
    Clin Infect Dis; 2015 Sep; 61(5):817-25. PubMed ID: 25977266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management.
    Verucchi G; Calza L; Manfredi R; Chiodo F
    Infection; 2004 Feb; 32(1):33-46. PubMed ID: 15007741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis C virus-human immunodeficiency virus coinfection.
    Sulkowski MS
    Liver Int; 2012 Feb; 32 Suppl 1():129-34. PubMed ID: 22212583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.
    Klein MB; Rollet KC; Hull M; Cooper C; Walmsley S; Conway B; Pick N;
    Antivir Ther; 2013; 18(5):717-21. PubMed ID: 23211632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.